MAPT and Cognitive impairment: In a subsequent secondary prevention study, P021 at 60 nmol/g feed in 3xTg-AD mice at the synaptic compensation stage starting from the age of 3 months up to 22 months of age was able to completely prevent synaptic and neurogenesis deficits, reduce neurodegeneration, and prevent cognitive impairment as well as Aβ and tau pathologies [204].